As AstraZeneca braces for the impact of the U.S. “most favored nation” drug pricing policy, CEO Pascal Soriot suggests that a ...
Teva’s overall performance topped Wall Street estimates for Q1, according to Bloomberg News, which also pointed out that the ...
Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology ...
In GSK’s first quarter with Luke Miels as CEO, the company’s flagship shingles vaccine Shingrix set a new quarterly sales ...
As regulatory delays continue to plague Regeneron’s efforts to develop Eylea, sales for the eye disease medicine remain in ...
As Ekterly nears the one-year anniversary of its FDA approval, Italy’s Chiesi Group is making moves to acquire the rare ...
Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
Earlier this year, when the FDA asked Amgen to pull its rare disease drug Tavneos from the market, the California drugmaker ...
When it comes to matching the commercial scale-up to the innovations taking place across Kite’s pipeline, Alquist admitted ...
Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...
Novartis CEO Vas Narasimhan says Europe needs a “complete rethink” of how it prices its drugs, warning that the entrance of ...
Rocket Pharmaceuticals has offloaded its lucrative FDA rare pediatric disease priority review voucher (PRV), striking a $180 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results